GDRX · GoodRx Holdings, Inc.

GoodRx's Q1 2026 results showed mixed performance with total revenue declining 4% to $194.0 million, primarily due to a 24% drop in prescription transactions revenue to $113.7 million. This was attributed to fewer Monthly Active Consumers from retail pharmacy store closures, volume reductions in integrated savings programs, and deliberate shifts toward long-term durability over short-term unit economics. Offsetting this, Pharma Direct revenue exploded 82% to $52.2 million through organic growth and expanded pharma manufacturer partnerships, particularly in consumer direct pricing, positioning it as a key growth driver. Subscription revenue grew 16% to $24.4 million, fueled by condition-specific programs launched in Q2 2025. GAAP net income fell to $1.2 million (0.6% margin) from $11.1 million (5.4% margin), while non-GAAP Adjusted EBITDA declined to $58.3 million (30.0% margin) from $69.8 million (34.4% margin), reflecting pressure on profitability. Operating cash flow improved to $11.8 million from $9.4 million. Balance sheet remains solid with $235.7 million in cash against $493.8 million debt. Management raised FY 2026 guidance to $765-$785 million revenue (from prior $796.9 million) and Adjusted EBITDA >$235 million, signaling confidence in strategic priorities. Share repurchases of 5.5 million shares for $12.6 million underscore capital return focus amid $60.2 million remaining authorization. CEO Wendy Barnes highlighted momentum in growth priorities, while CFO Chris McGinnis noted strong execution in Pharma Direct and subscriptions, supporting sustained growth and margins.